1014 related articles for article (PubMed ID: 30930892)
1. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.
Eckert F; Zwirner K; Boeke S; Thorwarth D; Zips D; Huber SM
Front Immunol; 2019; 10():407. PubMed ID: 30930892
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
4. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
5. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
6. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
7. The impact of hypoxia on immune state in cancer.
Mortezaee K; Majidpoor J
Life Sci; 2021 Dec; 286():120057. PubMed ID: 34662552
[TBL] [Abstract][Full Text] [Related]
8. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
[TBL] [Abstract][Full Text] [Related]
9. The Reciprocity between Radiotherapy and Cancer Immunotherapy.
Wang Y; Liu ZG; Yuan H; Deng W; Li J; Huang Y; Kim BYS; Story MD; Jiang W
Clin Cancer Res; 2019 Mar; 25(6):1709-1717. PubMed ID: 30413527
[TBL] [Abstract][Full Text] [Related]
10. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors.
Derer A; Frey B; Fietkau R; Gaipl US
Cancer Immunol Immunother; 2016 Jul; 65(7):779-86. PubMed ID: 26590829
[TBL] [Abstract][Full Text] [Related]
11. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
12. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
13. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
14. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
15. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy.
Li W; Zhan M; Quan YY; Wang H; Hua SN; Li Y; Zhang J; Lu L; Cui M
Int Immunopharmacol; 2020 Apr; 81():106227. PubMed ID: 32078941
[TBL] [Abstract][Full Text] [Related]
16. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Tamura R; Tanaka T; Akasaki Y; Murayama Y; Yoshida K; Sasaki H
Med Oncol; 2019 Nov; 37(1):2. PubMed ID: 31713115
[TBL] [Abstract][Full Text] [Related]
17. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.
van Gulijk M; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2759. PubMed ID: 30568653
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
19. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
